Introduction
============

Esophageal cancer (ESCA) ranks sixth in terms of cancer-associated mortality worldwide ([@b1-ol-0-0-11208]). In 2012, 455,000 patients were diagnosed with ESCA worldwide, translating to an incidence rate of 5.9 per 100,000 ([@b2-ol-0-0-11208]). The 5-year survival rate of patients with ESCA is only 18%, because ESCA typically exhibits no symptoms and is therefore diagnosed at an advanced clinical stage ([@b3-ol-0-0-11208]). At present, the top predictive characteristic of ESCA prognosis is TNM staging ([@b4-ol-0-0-11208]). Although TNM stage is useful, it varies among patients with the same cancer stage ([@b5-ol-0-0-11208]). Furthermore, clinicopathological characteristics are molecular comprehensive reflections, including proteins and genes. Patients with ESCA with homogeneous clinical stage may be further classified according to various molecular patterns, like a 6-microRNA signature reported by Lan *et al* ([@b6-ol-0-0-11208]). It is therefore crucial to determine novel biomarkers for identifying patients with high risk of mortality.

Long non-coding RNA (lncRNA) is defined as an RNA transcript that is not translated into proteins and of \>200 nucleotides in length ([@b7-ol-0-0-11208]). Conversely, with protein coding genes, the gene expression levels of reported lncRNAs are much lower ([@b8-ol-0-0-11208]). Furthermore, the role of lncRNAs is crucial in tumor growth, progression and treatment response ([@b9-ol-0-0-11208]), and most mRNAs serve critical roles in fundamental cellular processes. Numerous studies reported that integrated analysis of mRNAs and lncRNAs can contribute to the prognosis evaluation of breast and hepatocellular carcinoma ([@b10-ol-0-0-11208],[@b11-ol-0-0-11208]). However, only a few studies have focused on the integrated assessment of mRNAs and lncRNAs in ESCA.

The present study aimed to analyze the gene expression profile of ESCA samples from The Cancer Genome Atlas (TCGA) database, and a signature was constructed by integrating mRNA and lncRNA expression for the prediction of ESCA prognosis.

Materials and methods
=====================

### Data source and preprocessing

The TCGA database (accessed January 2019; <http://portal.gdc.cancer.gov/>) provided the RNA sequencing (RNA-seq) data and clinicopathological characteristics of patients with ESCA collected between December 2011 and December 2013 ([@b12-ol-0-0-11208]). The inclusion criteria were as follows: i) Patients with ESCA, RNA-seq data and clinicopathological information; and ii) patients with ESCA with at least 30 days follow-up. A total of 117 samples were selected in the present study, including 106 tumor tissues and 11 normal tissues ([Table SI](#SD1-ol-0-0-11208){ref-type="supplementary-material"}). Only RNAs with transcript per million value \>0.1 in ≥50% of ESCA samples were enrolled for further investigation. A total of 16,368 mRNAs and 7,347 lncRNAs were annotated according to GENCODE datasets ([www.gencodegenes.org](www.gencodegenes.org)). The differentially expressed (DE) mRNAs and lncRNAs in tumor tissues compared with normal tissues were analyzed using the 'limma' package (version 3.36.5; <http://bioconductor.org/packages/release/bioc/html/limma.html>) in R (version 3.5.2; <http://www.r-project.org/>). The results were visualized by volcano plot. Due to the gap between the count of mRNAs and lncRNAs, different thresholds were set for identifying DE mRNAs and lncRNAs. DEmRNAs with P\<0.05 and \|log fold change (FC)\|\>2.0, and DElncRNAs with P\<0.05 and \|log FC\|\>1.0 were considered as significant. The research process scheme is presented in [Fig. 1](#f1-ol-0-0-11208){ref-type="fig"}. Since the TCGA database information is publicly available, no ethical approval was required.

### Construction and validation of the mRNA-lncRNA signature

The prognostic values of mRNAs and lncRNAs were determined using univariate Cox proportional hazards regression analysis. According to previous studies, P\<0.1 was considered to indicate a statistically significant difference ([@b6-ol-0-0-11208],[@b13-ol-0-0-11208],[@b14-ol-0-0-11208]). Subsequently, a total of 106 tumor samples were randomly divided into two sets: A training set (n=53) and a test set (n=53; [Table I](#tI-ol-0-0-11208){ref-type="table"}).

The least absolute shrinkage and selection operator (LASSO) method, which is appropriate for high-dimensional data analysis ([@b15-ol-0-0-11208]), can select an optimal group of genes lacking collinearity through penalty imposing and most regression coefficients shrinking to zero. LASSO was therefore used in the training set to determine and confirm the selected mRNAs and lncRNAs. The prognostic mRNA-lncRNA signature risk score in patients was calculated using each prognostic RNA expression level and its associated coefficient. The formula used was as follow: Risk score=β1 × gene 1 + β2 × gene 2 +...+ βn × gene n, where β indicates the coefficient of each gene and gene indicates the expressed gene value.

Based on the median risk score cut-off (2.541), patients were divided into a high-risk group and a low-risk group. Kaplan-Meier (KM) and log-rank methods were used to test the difference in the two groups by using the 'survival' R package (version 2.43; <http://cran.r-project.org/web/packages/survival/index.html>). To validate the signature sensitivity and precision, the 'timeROC' R package (version 0.3; <http://cran.r-project.org/web/packages/timeROC/index.html>) was used to calculate the area under the receiver operating characteristic (ROC) curves. This signature was further validated in the test set and the entire set. Subsequently, stratified analysis based on the clinicopathological characteristics of patients with ESCA was carried out in the entire set.

### Development of the nomogram

The prognostic significance of the signature was evaluated with clinicopathologic characteristics, including age, sex, height, weight, pathology, alcohol consumption history, Barrett\'s disease and TNM stage, by univariate and multivariate Cox proportional hazard regressions analysis. In order to provide clinicians with a quantitative tool to predict the individual probability of survival time, the R package 'rms' (version 5.1--3; <http://cran.r-project.org/web/packages/rms/>) was used to build the nomogram associated with the variables, including a mRNA-lncRNA signature and TNM stage, derived from the previous analysis. Furthermore, the nomogram predictive performance was calculated using concordance index and bootstrapping validation calibration (1,000 bootstrap resamples) to reduce the potential of overfitting.

### mRNA-lncRNA signature function prediction

To study the potential biological mechanism between low- and high-risk groups, gene set enrichment analysis (GSEA; <http://software.broadinstitute.org/gsea>) was performed. The BioCarta (c2.cp.biocarta.v6.2.symbols.gmt) and Reactome (c2.cp.reactome.v6.2.symbols.gmt) datasets (<http://software.broadinstitute.org/gsea/msigdb/collections.jsp>) were selected as the reference gene sets. A gene with P\<0.05 and enrichment score \>0.5 was considered as significantly enriched.

Results
=======

### DEmRNAs and DElncRNAs in patients with ESCA

A total of 440 mRNAs were identified as significantly different between tumor and normal tissues, of which 93 mRNAs were upregulated and 347 were downregulated ([Fig. 2A](#f2-ol-0-0-11208){ref-type="fig"}). In addition, 263 DElncRNAs (51 upregulated; 212 downregulated) were identified and selected for further analysis ([Fig. 2B](#f2-ol-0-0-11208){ref-type="fig"}).

### Signature development in the training set

A total of 52 DEmRNAs and 38 DElncRNAs were identified in the training set as being associated with prognosis following univariate Cox proportional hazards regression analysis ([Table SII](#SD1-ol-0-0-11208){ref-type="supplementary-material"}). Furthermore, using the LASSO method, three mRNAs, PCNA, TNS4, SLC26A9, and two lncRNAs, ZFAS1, AC104041.1, were identified ([Fig. 3B](#f3-ol-0-0-11208){ref-type="fig"}). An appropriate value of lambda was set as 0.166 using cross validation ([Fig. 3A](#f3-ol-0-0-11208){ref-type="fig"}). The risk score calculated from the five expressed genes weighted by their coefficients was set as below: Risk score=(0.209095 × expression of PCNA) + (−0.023333 × expression of TNS4) + (−0.025136 × expression of SLC26A9) + (0.160318 × expression of ZFAS1) + (0.035372 × expression of AC104041.1).

According to the median risk score, patients were divided into high- and low-risk groups. The risk scores, survival time distributions and patients\' status in the training set are presented in [Fig. 4A](#f4-ol-0-0-11208){ref-type="fig"} (left panel). The results from KM survival analysis demonstrated that the two groups had significantly different outcomes ([Fig. 4A](#f4-ol-0-0-11208){ref-type="fig"}; right panel). In addition, 1-, 2- and 3-year time-dependent ROC analyses were performed to evaluate the mRNA-lncRNA signature prognostic sensitivity and specificity ([Fig. 4A](#f4-ol-0-0-11208){ref-type="fig"}; middle panel). The AUCs of the mRNA-lncRNA signature were 0.772, 0.837 and 0.851 at 1-, 2- and 3-year survival times, respectively, suggesting that this signature may have a high prognostic accuracy.

### Validation of the signature in the test and entire sets

By using the established cut-off point, patients were assigned to a low- or high-risk group in the test and entire sets. The patients\' risk score distribution and survival status were ranked by the risk scores in the test set ([Fig. 4B](#f4-ol-0-0-11208){ref-type="fig"}, left panel) and the entire set ([Fig. 4C](#f4-ol-0-0-11208){ref-type="fig"}, left panel). The results from KM analysis for overall survival (OS) indicated that patients with low risk may exhibit improved clinical outcomes compared with patients with high risk ([Fig. 4B and C](#f4-ol-0-0-11208){ref-type="fig"}, right panel). To confirm the accuracy of the signature, the areas under ROC curves were calculated, and the results were 0.728, 0.818 and 0.768 at 1-, 2- and 3-year survival times in the test set ([Fig. 4B](#f4-ol-0-0-11208){ref-type="fig"}, middle panel), respectively, and 0.756, 0.830, 0.829 at 1-, 2- and 3-year survival times in the entire set ([Fig. 4C](#f4-ol-0-0-11208){ref-type="fig"}, middle panel), respectively.

### Stratified analysis and independence analysis in the entire set

The results from subgroup analysis based on age, sex, height, weight, ethnicity, alcohol consumption history, Barrett\'s disease and TNM stage suggested that patients with high-risk of mortality may present with poor clinical outcomes. The results were all significant, except for women, non-white, no alcohol consumption history, tumor size I+II and stage I+II ([Fig. S1](#SD1-ol-0-0-11208){ref-type="supplementary-material"}). Furthermore, the mRNA-lncRNA signature was considered as an independent prognostic factor in univariate and multivariate Cox regression analyses in the entire set following adjustment for various clinicopathological characteristics \[hazard ratio (HR), 2.5, 95% confidence interval (CI), 1.55--4.06, P\<0.001 in the univariate Cox regression analysis; HR, 2.41, 95% CI, 1.47--3.96, P\<0.001 in the multivariate Cox regression analysis; [Table II](#tII-ol-0-0-11208){ref-type="table"}\].

### Construction of a novel nomogram for predicting prognosis in ESCA

Risk score and TNM stage derived from the previous analyses were developed and presented as a nomogram ([Fig. 5A](#f5-ol-0-0-11208){ref-type="fig"}). A high score of the nomogram indicated a high probability of 1- and 3-year survival. In the primary cohort, the nomogram C-index was 0.717 (95% CI, 0.543--0.891). The established nomogram calibration curve for the probability of survival outcome indicated good agreement between observation and prediction ([Fig. 5B and C](#f5-ol-0-0-11208){ref-type="fig"}).

### Functional analysis of the mRNA-lncRNA signature

In order to determine the possible signature mechanism, BioCarta and Reactome pathway enrichment analysis was performed using GSEA. The results demonstrated that compared with genes in the low-risk group, genes in the high-risk group were significantly enriched with numerous biological processes, in particular cell cycle signaling pathway, minichromosome maintenance pathway and mRNA capping and processing pathway ([Fig. 6](#f6-ol-0-0-11208){ref-type="fig"}).

Discussion
==========

Clinicopathological characteristics of patients with ESCA, including TNM stage, have been widely used to adapt individual treatment and predict prognosis for patients. However, due to the heterogeneity of ESCA, it is difficult to precisely predict prognosis by using clinicopathological characteristics ([@b16-ol-0-0-11208]). Therefore, application of gene-based biomarkers represents a promising alternative to predict prognosis.

Numerous studies have identified molecular markers for prognosis in ESCA. Peters *et al* ([@b17-ol-0-0-11208]) generated a 4-mRNA prognostic signature for patients with esophageal adenocarcinoma. Recently, a reliable 6-immunohistochemical-based signature has been determined for patients with esophageal squamous cell cancer ([@b18-ol-0-0-11208]). Furthermore, a 3-lncRNA signature associated with OS has been built for patients with esophageal squamous cell carcinoma ([@b19-ol-0-0-11208]). Fan *et al* ([@b20-ol-0-0-11208]) developed a novel 8-lncRNA signature for the prediction of prognosis in patients with ESCA. Additionally, a previous study reported that the dysregulated expression of certain micro (mi)RNAs (hsa-mir-425, hsa-let-7b, hsa-mir-23a, hsa-mir-3074, hsa-mir-424 and hsa-mir-505) could be used for the prognosis of esophageal adenocarcinoma ([@b6-ol-0-0-11208]). To the best of our knowledge, previous studies have only focused on mRNAs, lncRNAs or miRNAs, without investigating multi-RNA-based data. It is therefore crucial to assess whether multi-RNA-based signatures could predict prognosis in ESCA.

In the present study, a mRNA-lncRNA prognostic signature was established by conducting LASSO Cox regression model analysis. Based on the risk score of the signature, patients were divided into high- and low-risk groups. Patients in the low-risk group exhibited improved clinical outcomes. Furthermore, the mRNA-lncRNA signature was independent of the clinicopathological characteristics in univariate and multivariate Cox regression analyses.

The prognostic signature for patients with ESCA contained five genes, three mRNAs, PCNA, TNS4, SLC26A9, and two lncRNAs, ZFAS1, AC104041.1.

Among them, the genes proliferating cell nuclear antigen (PCNA), ZNFX1 antisense RNA 1 (ZFAS1) and AC10401.1 were negatively associated with OS, whereas the two other genes tensin 4 (TNS4) and solute carrier family 26 member 9 (SLC26A9) were associated with an improved survival outcome. PCNA has been identified as a proliferating cell nuclear antigen that can serve a role in DNA replication and repair ([@b21-ol-0-0-11208]). Furthermore, previous studies have identified PCNA as a cell growth marker and a predictive indicator of various types of cancer, including colorectal cancer, gastric carcinoma and parotid gland cancer ([@b22-ol-0-0-11208]--[@b24-ol-0-0-11208]). In addition, it has been reported that upregulated PCNA is associated with poor survival in patients with esophagus squamous cell cancer ([@b25-ol-0-0-11208]), which is consistent with the results from our previous study on ESCA. Furthermore, Kimos *et al* ([@b26-ol-0-0-11208]) identified PCNA as a biomarker of esophageal neoplastic progression, suggesting that PCNA could be a target for ESCA management. TNS4, which is identified as a COOH-terminus tensin-like molecule, has been reported to be a cell adhesion factor that is associated with cancer cell mobility and migration ([@b27-ol-0-0-11208]). Previous studies have demonstrated that TNS4 can promote cancer cell migration, and can be considered as an oncogene in hepatocellular cancer ([@b28-ol-0-0-11208]), pancreatic cancer ([@b29-ol-0-0-11208]) and colon carcinoma ([@b30-ol-0-0-11208]). Furthermore, none or lowly expressed TNS4 has been reported in kidney and prostate cancer ([@b31-ol-0-0-11208],[@b32-ol-0-0-11208]). These findings suggest the biological functions of TNS4 are dependent on the type of cancer. In the present study, reduced expression of TNS4 in ESCA samples was associated with short survival in patients. Regarding ZFAS1, its overexpression has been reported to be associated with metastasis and poor prognosis in gastric cancer ([@b33-ol-0-0-11208]), colorectal cancer ([@b34-ol-0-0-11208]) and hepatocellular carcinoma ([@b35-ol-0-0-11208]), suggesting that ZFAS1 may be considered as a potential prognostic marker in cancer. Consistently, the present study demonstrated that ZFAS1 expression was inversely associated with the OS of patients with ESCA. Regarding SLC26A9 and AC104041.1, there was no correlative literature in cancer. The biological role of these genes in ESCA should be further investigated.

The present study presented some limitations. Firstly, only 106 ESCA samples were available in the TCGA dataset, hence the sub-group sample size was too small. Secondly, the identified signature should be further validated in an external dataset. Thirdly, *in vitro* and *in vivo* experiments should be performed in order to better understand the potential mechanism of this signature.

In conclusion, the present study established and validated a mRNA-lncRNA integrated signature for the prognosis of patients with ESCA by using a TCGA dataset. Although further investigation is required to confirm the importance of this signature, the present study provided valuable information regarding ESCA pathology and its clinical management.
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![Overview of the analytic workflow of the present study. ESCA, esophageal carcinoma; LASSO, least absolute shrinkage and selection operator; lncRNA, long non-coding RNA; OS, overall survival; TCGA, The Cancer Genome Atlas.](ol-19-02-1434-g00){#f1-ol-0-0-11208}

![Volcano plot of differentially expressed (A) mRNAs and (B) lncRNAs between esophageal carcinoma and non-tumor tissues. The red points indicate upregulated genes and the blue points represent downregulated genes. lncRNA, long non-coding RNA.](ol-19-02-1434-g01){#f2-ol-0-0-11208}

![Texture feature selection using LASSO regression model. (A) Lambda selection in the LASSO model using 10-fold cross-validation. Dotted vertical lines on the left and right represent, respectively, the value with the minimum error and the largest lambda value where the deviance is within one standard error of the minimum. (B) LASSO coefficient profiles of the differentially expressed genes associated with the overall survival of patients with esophageal carcinoma. LASSO, least absolute shrinkage and selection operator.](ol-19-02-1434-g02){#f3-ol-0-0-11208}

![Construction and validation of the signature. Distribution of risk group, risk score and survival status (left panel), time dependent receiver operating characteristic curves at 1, 2 and 3 years (middle panel) and Kaplan-Meier survival analysis between high- and low-risk groups (right panel) in the (A) training, (B) test and (C) entire sets. AUC, area under the curve.](ol-19-02-1434-g03){#f4-ol-0-0-11208}

![Nomogram construction and validation. (A) Nomogram developed with risk score and TNM stage for 1- and 3-year survival probability in the primary cohort. Calibration curves of nomograms in terms of agreement between predicted and observed (B) 1- and (C) 3-year outcomes in the primary cohort. OS, overall survival.](ol-19-02-1434-g04){#f5-ol-0-0-11208}

![Gene enrichment analysis of the signature. (A) Pathways 'MCM', 'cell cycle' and 'G2' were significantly enriched using the gene set of 'C2.cp.biocarta.v6.2.symbols.gmt'. (B) Results from gene set enrichment analysis delineated signalling pathway associated with the mRNA-lncRNA signature using the gene set of 'c2.cp.reactome.v6.2.symbols.gmt'. Node size represents the number of genes enriched. Each node was colored according to the P-value. MCM, minichromosome maintenance.](ol-19-02-1434-g05){#f6-ol-0-0-11208}

###### 

Characteristics of patients in the training and test set.

  Variables                          Training set, n (%)   Test set, n (%)   P-value
  ---------------------------------- --------------------- ----------------- ---------
  Number                             53                    53                
  Age, years (mean ± SD)             65.00±12.41           64.06±12.34       0.695
  Sex                                                                        
    Female                           11 (20.8)             8 (15.1)          0.613
    Male                             42 (79.2)             45 (84.9)         
  Height, cm                                                                 
    \<175                            28 (57.1)             29 (59.2)         \>0.999
    \>175                            21 (42.9)             20 (40.8)         
    No value                         4                     4                 
  Weight, kg                                                                 
    \<80                             32 (60.4)             27 (51.9)         0.434
    \>80                             21 (39.6)             25 (48.1)         
    No value                         0                     1                 
  Ethnicity                                                                  
    Non-white                        3 (7.1)               7 (15.2)          0.320
    White                            39 (92.9)             39 (84.8)         
    No value                         11                    7                 
  Pathology                                                                  
    Adenocarcinoma                   40 (75.5)             35 (66.0)         0.393
    Squamous                         13 (24.5)             18 (34.0)         
  Alcohol history                                                            
    No                               17 (32.7)             15 (28.3)         0.675
    Yes                              35 (67.3)             38 (71.7)         
    No value                         1                     0                 
  Barrett\'s disease                                                         
    No                               34 (69.4)             40 (81.6)         0.240
    Yes                              15 (30.6)             9 (18.4)          
    No value                         4                     4                 
  T                                                                          
    1+2                              23 (44.2)             22 (42.3)         \>0.999
    3+4                              29 (55.8)             30 (57.7)         
    No value                         1                     1                 
  N                                                                          
    0                                16 (33.3)             16 (33.3)         \>0.999
    1+3                              32 (66.7)             32 (66.7)         
    No value                         5                     5                 
  M                                                                          
    0                                42 (87.5)             36 (83.7)         0.766
    1                                6 (12.5)              7 (16.3)          
    No value                         5                     10                
  Stage                                                                      
    I+II                             29 (54.7)             24 (48.0)         0.557
    III+IV                           24 (45.3)             26 (52.0)         
    No value                         0                     3                 
  Survival status                                                            
    Alive                            27 (50.9)             33 (62.3)         0.327
    Dead                             26 (49.1)             20 (37.7)         
  Survival time, years (mean ± SD)   1.47±1.35             1.34±1.16         0.606

###### 

Univariate and multivariate Cox regression analysis of risk score and clinical variables.

                                            Univariate analysis   Multivariate analysis                                 
  ----------------------------------------- --------------------- ----------------------- --------- ------ ------------ ---------
  Risk score                                2.50                  1.55--4.06              \<0.001   2.41   1.47--3.96   \<0.001
  Age (≥60 years vs. \<60 years)            0.68                  0.36--1.29              0.238                         
  Sex (male vs. female)                     1.70                  0.52--5.54              0.382                         
  Height (≥175 cm vs. \<175 cm)             1.15                  0.60--2.19              0.681                         
  Weight (≥85 kg vs. \<85 kg)               0.79                  0.41--1.51              0.471                         
  Pathology (squamous vs. adenocarcinoma)   1.04                  0.51--2.12              0.903                         
  Alcohol consumption (yes vs. no)          0.57                  0.30--1.08              0.083                         
  Barrett\'s disease (yes vs. no)           1.46                  0.74--2.88              0.271                         
  Stage (III+IV vs. I+II)                   2.09                  1.29--3.41              0.003     1.98   1.20--3.27   0.007

HR, hazard ratio.
